{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:42:13Z","timestamp":1783690933659,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-024-01943-3","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T18:30:06Z","timestamp":1734373806000},"page":"271-279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Albi score predicts overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with selective internal radiation therapy (SIRT)"],"prefix":"10.1007","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8153-3527","authenticated-orcid":false,"given":"Monica","family":"Finessi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cioffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fronda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Rovera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Passera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Carucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Rolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Rizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Colli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Maria","family":"Saracco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Calandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Daniela","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doriguzzi Breatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"3","key":"1943_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76(3):681\u2013693","journal-title":"J Hepatol"},{"key":"1943_CR2","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/hep.26014","volume":"57","author":"V Mazzaferro","year":"2013","unstructured":"Mazzaferro V et al (2013) Yttrium-90 radioembolization for intermediate\u2013advanced hepatocellular carcinoma: a phase 2 study. Hepatology 57:1826\u20131837","journal-title":"Hepatology"},{"issue":"3","key":"1943_CR3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/hep.24451","volume":"54","author":"B Sangro","year":"2011","unstructured":"Sangro B, Carpanese L, Cianni R et al (2011) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54(3):868\u2013878","journal-title":"Hepatology"},{"key":"1943_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem R et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497-507.e2","journal-title":"Gastroenterology"},{"key":"1943_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E et al (2021) Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 6:17\u201329","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1943_CR6","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M et al (2022) A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging 49:3340\u20133352","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1943_CR7","first-page":"2021","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R et al (2021) Yttrium-90 radioembolization for the treatment of solitary. Unresectable HCC: The LEGACY Study 74:2021","journal-title":"Unresectable HCC: The LEGACY Study"},{"key":"1943_CR8","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00259-019-04340-5","volume":"46","author":"R Salem","year":"2019","unstructured":"Salem R et al (2019) Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 46:1695\u20131704","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1943_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2191-219X-3-1","volume":"3","author":"YH Kao","year":"2013","unstructured":"Kao YH et al (2013) Post-radioembolization yttrium-90 PET\/CT-part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res 3:1\u201327","journal-title":"EJNMMI Res"},{"key":"1943_CR10","first-page":"1","volume":"1","author":"C Child","year":"1964","unstructured":"Child C, Turcotte J (1964) Surgery and portal hypertension. Major Probl Clin Surg 1:1\u201385","journal-title":"Major Probl Clin Surg"},{"key":"1943_CR11","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020\u20131022","journal-title":"Hepatology"},{"key":"1943_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1055\/s-2008-1040325","volume":"28","author":"F Durand","year":"2008","unstructured":"Durand F, Valla D (2008) Assessment of prognosis of cirrhosis. Semin Liver Dis 28:110\u2013122","journal-title":"Semin Liver Dis"},{"key":"1943_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"P Johnson","year":"2015","unstructured":"Johnson P et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550\u2013558","journal-title":"J Clin Oncol"},{"key":"1943_CR14","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.3748\/wjg.v29.i32.4873","volume":"29","author":"H Navadurong","year":"2023","unstructured":"Navadurong H et al (2023) Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis. World J Gastroenterol 29:4873\u20134882","journal-title":"World J Gastroenterol"},{"key":"1943_CR15","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1002\/hep4.2072","volume":"6","author":"M Reincke","year":"2022","unstructured":"Reincke M et al (2022) Hepatic decompensation after transarterial radioembolization: a retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma. Hepatol Commun 6:3223\u20133233","journal-title":"Hepatol Commun"},{"issue":"15","key":"1943_CR16","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.3390\/cancers13153794","volume":"13","author":"C Lescure","year":"2021","unstructured":"Lescure C et al (2021) Albi score is a strong predictor of toxicity following sirt for hepatocellular carcinoma. Cancers 13(15):3794. https:\/\/doi.org\/10.3390\/cancers13153794","journal-title":"Cancers"},{"key":"1943_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.14744\/hf.2022.2022.0036","volume":"4","author":"S Evirgen","year":"2023","unstructured":"Evirgen S et al (2023) Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin\u2013bilirubin score\u2019s prediction factor for survival? Hepatology Forum 4:103\u2013107","journal-title":"Hepatology Forum"},{"key":"1943_CR18","doi-asserted-by":"publisher","first-page":"840","DOI":"10.21037\/jgo.2018.05.14","volume":"9","author":"H Mohammadi","year":"2018","unstructured":"Mohammadi H et al (2018) Using the albumin\u2013bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma. J Gastrointest Oncol 9:840\u2013846","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"1943_CR19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/cancers11060879","volume":"11","author":"M Antkowiak","year":"2019","unstructured":"Antkowiak M et al (2019) Prognostic role of albumin, bilirubin, and ALBI scores: analysis of 1000 patients with hepatocellular carcinoma undergoing radioembolization. Cancers 11(6):879. https:\/\/doi.org\/10.3390\/cancers11060879","journal-title":"Cancers"},{"key":"1943_CR20","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M et al (2022) EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 49:1682\u20131699","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1943_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev.publhealth.20.1.145","volume":"20","author":"L Fisher","year":"1999","unstructured":"Fisher L, Lin D (1999) Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 20:145\u2013157","journal-title":"Annu Rev Public Health"},{"key":"1943_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","volume":"66","author":"DJ Pinato","year":"2017","unstructured":"Pinato DJ et al (2017) The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 66:338\u2013346","journal-title":"J Hepatol"},{"key":"1943_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jvir.2016.03.005","volume":"27","author":"R Hickey","year":"2016","unstructured":"Hickey R et al (2016) Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma. J Vasc Interv Radiol 27:795\u2013802","journal-title":"J Vasc Interv Radiol"},{"key":"1943_CR24","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/COC.0000000000000384","volume":"41","author":"B Gui","year":"2018","unstructured":"Gui B et al (2018) Assessment of the albumin\u2013bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization. American J Clin Oncol: Cancer Clin Trials 41:861\u2013866","journal-title":"American J Clin Oncol: Cancer Clin Trials"},{"key":"1943_CR25","first-page":"2342","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R et al (2021) Yttrium-90 radioembolization for the treatment of solitary. Unresectable HCC: The LEGACY Study Hepatol 74:2342\u20132352","journal-title":"Unresectable HCC: The LEGACY Study Hepatol"},{"key":"1943_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","volume":"59","author":"M Vouche","year":"2013","unstructured":"Vouche M et al (2013) Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 59:1029\u20131036","journal-title":"J Hepatol"},{"issue":"5","key":"1943_CR27","doi-asserted-by":"publisher","first-page":"100347","DOI":"10.1016\/j.jhepr.2021.100347","volume":"3","author":"CO Demirtas","year":"2021","unstructured":"Demirtas CO, D\u2019Alessio A, Rimassa L, Sharma R, Pinato DJ (2021) ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Reports 3(5):100347. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100347","journal-title":"JHEP Reports"},{"key":"1943_CR28","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH et al (2018) SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 36:1913\u20131921","journal-title":"J Clin Oncol"},{"key":"1943_CR29","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.ejmp.2016.10.023","volume":"32","author":"E Gallio","year":"2016","unstructured":"Gallio E et al (2016) Calculation of tumour and normal tissue biological effective dose in 90Y liver radioembolization with different dosimetric methods. Physica Med 32:1738\u20131744","journal-title":"Physica Med"},{"issue":"10","key":"1943_CR30","doi-asserted-by":"publisher","first-page":"8774","DOI":"10.3390\/curroncol30100633","volume":"30","author":"M Cerreto","year":"2023","unstructured":"Cerreto M et al (2023) The new era of systemic treatment for hepatocellular carcinoma: from the first line to the optimal sequence. Curr Oncol 30(10):8774\u20138792","journal-title":"Curr Oncol"},{"issue":"12","key":"1943_CR31","doi-asserted-by":"publisher","first-page":"10100","DOI":"10.3390\/curroncol30120734","volume":"30","author":"A Villalobos","year":"2023","unstructured":"Villalobos A et al (2023) Safety and efficacy of concurrent atezolizumab\/bevacizumab or nivolumab combination therapy with Yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma. Curr Oncol 30(12):10100\u201310110","journal-title":"Curr Oncol"},{"issue":"12","key":"1943_CR32","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.14309\/ajg.0000000000002467","volume":"118","author":"YH Yeo","year":"2023","unstructured":"Yeo YH et al (2023) Immunotherapy and transarterial radioembolization combination treatment for advanced hepatocellular carcinoma. Am J Gastroenterol 118(12):2201\u20132211","journal-title":"Am J Gastroenterol"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01943-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-024-01943-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01943-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T10:51:40Z","timestamp":1740739900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-024-01943-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1007\/s11547-024-01943-3","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}},{"value":"Patients were informed that their clinical and imaging data could have been used for retrospective research purposes and gave their written consent for usage and publication in an anonymized form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of A.O.U. Citt\u00e0 della Salute e della Scienza di Torino (2CEI-452; 26 January 2022).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}